Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPz Cussons Regulatory News (PZC)

Share Price Information for Pz Cussons (PZC)

Share Price is delayed by 15 minutes
Get Live Data
87.40    2.10 (2.46%)
Bid:
87.00
Ask:
88.90
Spread: 1.90 (2.184%)
Market Cap: £367.39m
PZC Live PriceLast checked at - London Stock Exchange

Intraday Pz Cussons Share Chart

Interim Management Statement

19 Sep 2011 07:00

RNS Number : 4315O
PZ CUSSONS PLC
19 September 2011
 



19 September 2011

 

PZ Cussons Plc

(the "Group")

 

Interim Management Statement

 

PZ Cussons Plc today issues the following interim management statement which covers the period 1 June 2011 to 18 September 2011, in advance of its Annual General Meeting, to be held at 10:30am today.

 

Overview of financial position and performance

 

The Board is pleased to announce that the performance of the Group during the period has been in line with management expectations. The financial position of the Group remains strong with cash generation during the period also in line with expectations.

 

Trading Update

 

Europe

 

In the UK, trading in the core washing and bathing division has been robust although margins continue to be impacted by high promotional and raw material costs. New products to be launched at higher margins over the coming months include a new Carex range featuring advanced technology that continues to kill bacteria up to two hours after use.

 

The beauty division is trading well across the three brands of Sanctuary, St Tropez and Charles Worthington with good growth in the US offsetting tougher trading conditions in some UK distribution channels. New products to be launched include a Charles Worthington 'Salon at Home' range which will go into distribution in the UK and US over the coming months.

 

Performance in Poland and Greece has also been in line with expectations.

 

Asia

 

The positive momentum experienced in Indonesia in the second half of last year has continued with further growth in revenue and profitability.

 

Performance in Indonesia is helping to offset poorer trading conditions in Australia which have continued to worsen in our core categories with profitability further impacted by higher raw material costs.

 

Africa

 

The positive growth momentum has also continued in Nigeria across all business units of Home and Personal Care (HPC), Electricals and Food and Nutrition, although margins in HPC in particular have been impacted by the full effect of the continued rise in raw material costs.

 

Construction of the palm oil refinery with Wilmar in Nigeria is on schedule with completion due by the end of the 2012 calendar year.

 

Financial Position

 

The financial position of the Group is strong with a continuing net funds position. Normal capital expenditure is at the level of depreciation with the only additional project being the £17m investment in the joint venture with Wilmar in Nigeria.

 

Summary

 

The overall performance and position of the Group at the end of the period is in line with management expectations.

 

Trading momentum in most markets is positive giving cause for optimism. Margins continue to be affected by raw material cost increases with initiatives underway to recover these through higher selling prices and margin improvement projects.

 

A further update on the Group's performance will be given in the interim financial statements for the six months to 30 November 2011, to be announced at the end of January 2012.

 

 

- Ends -

 

For further information contact:

 

PZ Cussons Plc Tel: 0161 435 1016

Brandon Leigh

 

MHP Tel: 020 3128 8100

John Olsen /James White

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDKADPPBKDQCD
Date   Source Headline
25th Sep 20193:57 pmRNSResult of AGM
25th Sep 20197:00 amRNSAGM Trading Statement
29th Aug 20197:00 amRNSProposed sale of Minerva and Luksja brand
23rd Aug 201912:15 pmRNSPublication of ARA and Notice of AGM
26th Jul 20198:45 amRNSDirector/PDMR Shareholding
23rd Jul 20197:00 amRNSFinal Results
13th Jun 20197:00 amRNSBoard Change
13th Jun 20197:00 amRNSTrading update
30th Apr 20195:30 pmRNSDirector/PDMR Shareholding
18th Apr 20197:00 amRNSTrading Update
28th Mar 201912:15 pmRNSDirector Declaration
14th Mar 201910:00 amRNSPZ Cussons Plc Director Declaration
30th Jan 201911:10 amRNSInterim Dividend Payment Date
29th Jan 20197:00 amRNSHalf-year Report
23rd Jan 20198:10 amRNSDirector Declaration
13th Dec 20187:00 amRNSTrading Update
13th Nov 201811:09 amRNSHolding(s) in Company
26th Sep 20184:25 pmRNSResult of AGM
26th Sep 20187:00 amRNSAGM Trading Statement
6th Aug 20185:30 pmRNSDirector/PDMR Shareholding
30th Jul 20185:19 pmRNSDirector/PDMR Shareholding
26th Jul 20184:05 pmRNSDirector/PDMR Shareholding
26th Jul 20183:15 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSTrading update
2nd May 20187:00 amRNSChange to the Board of Directors
15th Mar 20187:00 amRNSTrading Update
30th Jan 20187:00 amRNSInterim Results
4th Jan 20184:41 pmRNSDirectorate Change
14th Dec 20177:00 amRNSTrading Update
7th Dec 201710:42 amRNSHolding(s) in Company
5th Dec 201710:49 amRNSHolding(s) in Company
27th Sep 20175:30 pmRNSAGM Statement
27th Sep 20177:00 amRNSAGM Trading Statement
30th Aug 20175:30 pmRNSDirector/PDMR Shareholding
28th Jul 20175:30 pmRNSHolding(s) in Company
27th Jul 201711:03 amRNSDirector/PDMR Shareholding
25th Jul 20177:01 amRNSBoard Changes
25th Jul 20177:00 amRNSFinal Results
15th Jun 20177:00 amRNSTrading Update
13th Apr 20177:00 amRNSTrading Update
24th Mar 20177:00 amRNSAppointment of Deloitte LLP as Auditor
13th Mar 201712:24 pmRNSDirector/PDMR Shareholding
1st Feb 20178:45 amRNSDirector/PDMR Shareholding
26th Jan 20175:30 pmRNSDirector/PDMR Shareholding
25th Jan 20175:30 pmRNSDirector/PDMR Shareholding
24th Jan 20177:00 amRNSHalf-year Report
15th Dec 20167:00 amRNSTrading Update
12th Oct 20167:00 amRNSAppointment of a new Non-executive Director
3rd Oct 20164:25 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.